Case report

Endobronchial mucosal nodular lesions in allergic bronchopulmonary aspergillosis

Fumiya Nihashi a, Toshiya Hiramatsu a, Tomohiro Uto a, Jun Sato a, Shiro Imokawa a, *, Takafumi Suda b

a Division of Respiratory Medicine, Iwata City Hospital, 512-3 Ookubo, Iwata, Shizuoka, 438-8550, Japan
b Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handa-yama, Higashi-ku, Hamamatsu, 431-3192, Japan

ARTICLE INFO

Keywords:
Aspergillus fumigatus
Eosinophilic granulomatosis with polyangiitis
Eosinophilic pneumonia
Mucoid impaction

ABSTRACT

Bronchoscopic findings often show mucoid impaction in patients with allergic bronchopulmonary aspergillosis (ABPA); however, endobronchial mucosal nodular lesions have not been reported. We herein present the first such case of a 52-year-old woman with ABPA and endobronchial mucosal nodular lesions. The endobronchial lesions were located in the orifice of the mucoid impaction, and disappeared after 4 weeks of treatment with prednisolone and itraconazole. Aspergillus fumigatus was cultured from bronchial lavage fluid collected from the site of mucoid impaction. Based on these clinical findings, we speculate that the bronchial lesions were caused by an inflammatory and allergic reaction to Aspergillus antigens.

1. Introduction

In patients with eosinophilic pneumonia or eosinophilic granulomatosis with polyangiitis, bronchoscopic findings show mucosal nodular lesions in the trachea and main bronchus [1–3]. The pathologic findings in such patients usually comprise eosinophilic inflammation, edematous changes, and/or necrotizing bronchial inflammation [1–3]. However, these bronchial nodular lesions have not been reported in patients with allergic bronchopulmonary aspergillosis (ABPA). We herein report the case of a patient with ABPA with endobronchial mucosal nodular lesions that disappeared after treatment with prednisolone and itraconazole.

2. Case report

A 52-year-old woman was referred for evaluation of abnormal chest shadows. She had a history of rheumatoid arthritis (RA) that had been treated with low-dose prednisolone and salazosulfapyridine. She also had a history of breast cancer. The patient had never smoked, and had no history of bronchial asthma. Chest computed tomography showed highly attenuated, mucus-filled, dilated bronchi (Fig. 1). Laboratory examination revealed an eosinophil count of 821.5/μL, a total IgE level of 1656 IU/mL, and positivity for Aspergillus-specific IgE and precipitating antibody. An immediate skin test for Aspergillus yielded a positive reaction. MPO-ANCA and PR3-ANCA were negative. Fractional exhaled nitric oxide level was elevated to 48 ppb. A lung function test revealed as follows: FVC 2.40 (L), %FVC 90.2%, FEV1 2.03 (L), %FEV1 86.4%, and FEV1/FVC 84.6%. Threshold of methacholine was 20,000 μg/mL. Bronchoscopy revealed multiple nodular mucosal lesions in the orifice of the right B2 bronchus (Fig. 2a). Histopathologic examination showed edematous changes and bronchial inflammation with eosinophils (Fig. 3a and b). Mucoid impaction was noted in the distal aspect of the right bronchus (Fig. 2b), and Aspergillus fumigatus (A. fumigatus) was cultured from the bronchial lavage fluid. There were no clinical findings of vasculitis. The patient was diagnosed with ABPA [4], and treated with oral prednisolone (30mg/day) and itraconazole (400mg/day). Four weeks of treatment resulted in resolution of the endobronchial lesions and the mucoid impaction (Fig. 2c). Prednisolone was slowly tapered off and itraconazole was continued for 16 weeks. A 4-month follow up chest computed tomography scan showed almost complete resolution of the highly attenuated intrabronchial mucus, and bronchiectasis was noted (Fig. 4). Peripheral eosinophil count and total IgE level were decreased to 70.0/μL and 93 IU/mL, respectively.

3. Discussion

In patients with ABPA, bronchoscopy usually show intraluminal retention of inspissated mucoid secretions, which is known as mucoid
impaction [5]. The airway walls around this area of mucoid impaction often have inflammatory and edematous changes [5]. In addition to these findings, our patient had multiple nodular mucosal lesions in the orifice. This is the first report of these bronchoscopic findings in a patient with ABPA.

A few previous reports have described similar endobronchial mucosal nodular lesions in patients with eosinophilic pneumonia and eosinophilic granulomatosis with polyangiitis [1–3]. The pathologic findings in these previous cases were necrotizing bronchial inflammation with eosinophils and thickening of the basement membrane [1–3]. In our case, histologic examinations of the bronchial nodular lesions revealed edematous change and eosinophilic infiltrations. Epithelial cells were denuded, but there were no tissue necrosis. Aspergillus hyphae were not detected in this specimens. These pathological findings were nonspecific, but may suggest that these bronchial mucosal lesion represent a localized accentuation of edema associated with eosinophilic inflammation.

The pathogenesis of ABPA is not completely understood, but the condition is thought to occur due to abnormal exaggerated local and systemic immune response to Aspergillus antigens [4]. Recently, Muniz VS et al. reported that eosinophil extracellular DNA trap (EET) have been noted in the airway mucus in patients with ABPA [6]. They also demonstrated that human eosinophils release EETs in response to A. fumigatus [6]. EETs are derived from eosinophil extracellular DNA trap cell death (EETosis) [7] and provide adhesive surface that can entrap intact eosinophil granules and microorganisms [7], but lack the killing or fungistatic activities against A. fumigatus [6]. In our case, the lesions of interest were located only near the mucoid impaction, from which A. fumigatus was cultured. Therefore, we speculate that these endobronchial mucosal nodular lesions may have been caused by an inflammatory and allergic reaction to Aspergillus antigens. Free granules entrapped in EETs may cause long-lasting bronchial wall inflammation leading to epithelial cell damage. However, the precise mechanisms are unclear and require further investigation.

Funding

I declare that all authors have received no support in the form of grants, gifts, equipment, or drugs about this case report.

Declaration of competing interest

I declare on behalf of my co-authors and myself that we do not have
any conflict of interest to declare.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.rmcr.2019.100975.

References

[1] M. Toyoshima, T. Suda, K. Chida, Tracheobronchial involvement in chronic eosinophilic pneumonia, Am. J. Respir. Crit. Care Med. 186 (2012) 1057.
[2] J. Hara, K. Nishi, Y. Demura, K. Kurumaya, K. Katayanagi, K. Kasahara, M. Fujimura, S. Nakao, Chronic eosinophilic pneumonia with endobronchial involvement, J Bronchol Intervent Pulmonol 18 (2011) 285–287.
[3] H. Matsushima, N. Takayanagi, K. Kurashima, D. Tokunaga, M. Ubukata, Y. Kawabata, Y. Sugita, Multiple tracheobronchial mucosal lesions in two cases of Churg-Strauss syndrome, Respirology 11 (2006) 109–112.
[4] K. Patterson, M.E. Strek, Allergic bronchopulmonary aspergillosis, Proc. Am. Thorac. Soc. 7 (2010) 237–244.
[5] R. Krenke, E.M. Grabczak, Tracheobronchial manifestations of Aspergillus infections, Sci. World J. 11 (2011) 2310–2329.
[6] V.S. Muniz, J.C. Silva, Y.A.V. Braga, R.C.N. Melo, S. Ueki, M. Takeda, A. Hebisawa, K. Asano, R.T. Figueiredo, J.S. Neves, Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus, J. Allergy Clin. Immunol. 137 (2016) 258–267.